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Introduction
Human Embryonic Stem Cells (hESC) are vigorously
investigated as a source for cell replacement therapies. In
order to deliver on their promise large amounts of high
quality hESC will be needed that are genetically stable, free
of animal products and manipulated to evade the immune
system through either SCNT or other technologies. Here we
will review several aspects of hESC biology that may
directly or indirectly affect their genetic stability.
hESC Culture Conditions
Human embryonic stem (hESC) cell lines are established
from the inner cell mass (ICM) of the blastocyst and
differentiate into all cell lineages of the body [29, 31]. They
were initially derived in 1998 and have enormous potential
as a source of cells for cell replacement therapies and as a
model for early human development [13]. Two culture
conditions are widely used to propagate hESC. The
standard method of culturing hESC stock cultures involves
weekly mechanical passaging of morphologically undiffer-
entiated appearing parts of a hESC colony onto full density
(6×104 cell/cm2) mouse or human fibroblast feeder layers
in a medium containing 20% FCS [29, 31]. This protocol,
albeit time, money and effort intensive, has proven to be a
safe and reliable method for the long term propagation of
hESC. This is highlighted by the fact that hESC thus
cultured have never been reported to develop genetic
abnormalities during culture. However, the major drawback
of this method is the low number of hESC available for
experimentation. Most laboratories therefore opt to main-
tain hESC stock cultures using this standard method and
regularly establish fresh bulk cultures from these stocks for
experimentation [2]. Bulk culture of hESC is performed
according to a method developed by Amit et al. which
involves passaging of enzymatically (collagenase, trypsin,
etc) or non-enzymatically (cell dissociation solution,
EDTA, etc) dissociated clumps of hESC on 1/3 density
feeders (2×104 cell/cm2) in KSOR with 20% serum
replacement. This method indeed allows for dramatic
expansion of hESC (Fig. 1). However, a number of reports
have indicated that this is accompanied by an increase in
genetic instability, methylation changes and mitochondrial
mutations, abnormalities also seen in cancer and Embryo
Carcinoma (EC) cells (the transformed counterpart of
hESC) [5, 8, 24]. Since large amounts of undifferentiated
stem cells of high quality will be needed for regenerative
medicine approaches in the future, a deeper understanding
of the molecular mechanisms that control the genetic
stability of hESC is required. In addition culture methods
that prevent the occurrence of genetic instability and/or
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technologies to purge abnormal hESC from large scale
hESC cultures will have to be developed.
Pre-existing versus Acquired Genetic Abnormalities?
The fact that hESC cultured under standard conditions
display such remarkable genetic stability (normal karyo-
types for over 200 weekly passages) as compared to bulk
cultured cells (frequent abnormal karyotypes between
passage 20 and 60) suggests fundamental differences
between these two culture systems. One can envisage two
broad possible explanations for the occurrence of genetic
abnormalities in bulk cultured hESC. (1) Bulk culture
directly or indirectly causes genetic instability (2) Genetic
instability is an intrinsic feature of hESC in general but the
phenotype of genetically abnormal cells only becomes
apparent in bulk cultured hESC. If (1) is correct and the
abnormalities occur as a consequence of the bulk culture
conditions then bulk cultured hESC should be found to
Fig. 1 Comparison of “Stan-
dard” culture method with
“Bulk”-culture method. See text
for detailed explanation
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exhibit a combination of increased mutagenesis, reduced
apoptosis, reduced DNA-repair and enhanced growth/
survival properties as compared to hESC grown in standard
conditions. If (2) is correct and hESC grown under standard
conditions show similar intrinsic genetic instability as bulk
cultured hESC then one would predict that standard grown
hESC exhibit more efficient mechanisms to delete/suppress
abnormal cells, display enhanced repair DNA or that the
acquired genetic abnormalities do not confer sufficient
growth/survival enhancement under standard conditions to
take over the culture. In order to test these hypotheses
described above CGH arrays, SNP arrays and high through
put whole genome sequencing will have to be employed in
the future because the method that is most widely used to
assess genetic stability of hESC at present is G-banding
karyotype analysis. This method is only a low resolution
assay, as 5–10% of all cells analysed need to show an
abnormal karyotype to call the hESC genetically abnormal
and does not identify small deletions or mutations.
Can We Phenotypically Distinguish Genetically Normal
and Abnormal hESC?
Embryocarcinoma (EC) cells are the transformed geneti-
cally unstable counterpart of hESC and characteristically
display very similar cytogenetic abnormalities to hESC
with acquired genetic abnormalities such as trisomy 12, 17
and X [5, 8, 24]. How then does one define a genetically
healthy hESC? Some would argue that it is the ability to
form teratomas with representatives of all three germ
lineages that identifies the stem cell. However, EC cells
also exhibit this property with the difference that undiffer-
entiated primitive cells are still present in the graft that can
be transplanted to new recipients, identifying them as a
teratocarcinoma. However, since this particular experiment
is usually not performed with hESC teratomas it is difficult
to determine whether the hESC were actually stem cells or
EC cells. Indeed, in the majority of reports there are only
high power images of differentiated hESC shown and no
overview of what other (undifferentiated?) cell types are
present in such grafts. Others would argue that the
expression of stem cell markers is proof of the presence
of hESC. However, EC cells also express pluripotency
markers and hESC with genetic abnormalities, such as ones
that are marked by CD30 (see section below), actually
display higher marker expression (>95%) than genetically
healthy hESC (>70–80%) which usually display 15–20%
spontaneous background differentiation. The presence of a
fraction of spontaneously differentiating hESC in culture
may therefore be a better indication of a genetically healthy
hESC culture than hESC that express unusually high levels
of pluripotency markers. This phenomenon is exacerbated
by the high proliferative potential of high pluripotency
marker expressing hESC. Indeed our data indicate that the
more undifferentiated a hESC line is, the faster it grows
(Filipczyk et al. pers. comm.) Unfortunately this also
applies to hESC with abnormally high pluripotency marker
expression that more closely resemble EC cells. Such cells
would therefore rapidly take over the culture and without
good assays to discriminate hESC from EC cells or from
ES cells with genetic alterations that do not show up in G-
banding karyotype analyses one could easily interpret the
properties of such genetically compromised cells for
those of hESC cells.
Selective Pressures During Establishment
of HES Cell Lines
Since we can not rule out the possibility that genetically
compromised hESC are present from the inception of a
hESC culture and because genetically abnormal hESC have
a growth/survival/differentiation advantage over genetically
“healthy” hESC it may be informative to consider the
history of the cells and the selective pressures placed upon
hESC cultures during their establishment and subsequent
propagation (Fig. 2). hESC are cells isolated from the inner
cell mass of day 5 blastocysts procured from to be
discarded excess IVF embryos [29, 31]. The first decision
in the history of a hESC line is therefore made at the oocyte
stage when good quality oocytes are selected for IVF. In
general the best fertilized cells are selected for implantation
while the left over eggs with a potentially lower quality
score can then made available for stem cell research. Post
fertilization only some of the excess zygotes subsequently
progress to blastocyst stage for reasons that are not fully
understood at present. The next step in the establishment of
a hESC line involves the selection of blastocysts with a
high standard scoring classification (i.e. symmetry and low
levels of cell fragmentation (apoptosis). Apoptosis of ICM
cells is thought to be part of a quality control program
perhaps aimed at eliminating abnormal cells from the
developing embryo. This is supported by the observation
that the incidence of apoptosis in in vitro produced embryos
is increased by suboptimal culture conditions. Indeed, 7–
8% of cells in pre-implantation embryos undergo apoptosis
during this time and this occurs mainly in the ICM [11].
Nevertheless, early human development is accompanied by
a high degree of genetic abnormality, with one third of first
trimester miscarriages attributed to chromosomal defects
[23]. To our knowledge to date there has been no
systematic investigation into the potential correlation
between the level of ICM apoptosis at the blastocyst stage
and their subsequent ability to establish hESC lines or how
this relates to their long term genetic stability. However,
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several studies have correlated the occurrence of chromo-
some abnormalities in SCNT embryos with the frequency
of abnormalities in the donor cell line [22]. Donor cell lines
with a higher percentage of genetically abnormal cells were
found to cause a higher rate of chromosomally abnormal
blastomeres in the SCNT embryos. It would be interesting
to determine whether donor nuclei with chromosomal
amplifications also detected in hESC (such as trisomy 12,
17, or X) show an enhanced ability to establish ES-cell
lines. Following immuno-surgery and isolation of the inner
cell mass, the next stage of hES derivation involves the
propagation of isolated clumps of inner cell mass cells after
plating on full density mouse or human fibroblast feeder
layers. Again only a subset of these clumps can be coaxed
into becoming a hESC line with rather low frequency. It
seems self-evident that during this step there is a selection
for cells that can respond to the maintenance factors
excreted by the feeder layers and the medium components
that aid in the establishment of hESC lines. In addition one
would select for hESC that exhibit low apoptosis and a low
propensity to differentiate since these are the cells that have
the highest proliferative capacity. There is a large body of
circumstantial evidence to suggest that mES lines adapt to
their culture conditions and that various strains or sub-
strains differ in their ability to generate ES cell lines or to
contribute to the germline. Indeed, some mouse strains
appear unable to establish mES lines, although the exact
rationale for this phenomenon remains unknown. Although
these parameters are not easy to assess in a human context
it is not unreasonable to infer that a similar process occurs
with hESCs. In addition there is a school of thought that
argues that this selection is related to the occurrence of
specific genetic and epigenetic changes that may aid in this
adaptation to in vitro culture. As argued above hESC may
have an innate ability to adapt to culture conditions or that
certain culture conditions select for hESC with properties
that allow propagation in a particular culture method. Since
hESCs generally do not proliferate as single cells but rather
as small clumps there is a possibility that hESC lines are
intrinsically heterogeneous for this very reason from their
Fig. 2 The sequence of poten-
tial selective pressures during
the establishment of a hESC
culture. Excess oocytes not se-
lected for reproduction are made
available for hESC establish-
ment. A subset of fertilized
embryos progresses to blasto-
cyst stage. Inner cell mass cells
are selected for low apoptotic
index. A subset of hESC pro-
ceeds to form a cell line after
immunosurgery. A subset of
hESC responds to MEF secreted
maintenance factors and media
components. Further selection of
hESC occurs during culture
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inception. Indeed, the vast majority of hESC lines have not
been derived from a single clone. An in depth analysis of
the genetic heterogeneity within hESC lines is further
complicated by the fact that hESCs cultured under the
standard most optimal culture conditions rapidly become a
heterogeneous population of cells when analysed at the
gene expression level. Transcriptome analysis of gene
expression in hESC stratified on the basis of their
expression of known pluripotency marker expression shows
that hESCs are not only in a constant flux of spontaneous
differentiation, as judged by the presence of 20% of
differentiated cells under these conditions, but indeed
display substantial differences in mRNA expression [19]
as compared to hESC with lower, but still positive,
expression of the pluripotency markers. Indeed, transcrip-
tome analysis of FACS sorted hESC stratified on the basis
of the highest expression of pluripotency markers indicates
that that these ultra-stem cells already express supposedly
lineage specific markers such as nestin and brachyury by
array analysis and RT-PCR, albeit at low levels.
Chromosomal Abnormalities and Potential Significance
Although the original reports on HESCs indicated that they
can maintain a normal diploid karyotype, there is evidence
that this depend on culture conditions. Different laborato-
ries have reported that HESCs cultured for long periods of
time tend to gain chromosomal abnormalities, resembling
the ones observed in hEC cells. The most frequently
observed karyotypic abnormalities are gain of chromosome
17q, 12 and X chromosome [5, 8, 24], while there also
seems to be a high proportion of partial or total chromo-
some 1 duplication. It has been postulated that increased
dosage of those chromosomes might give the cells some
sort of selective advantage.
Draper et al. [8] were the first to report gain of
chromosome 17q and chromosome 12 in H7 and H14 cell
lines cultured with Knockout SR replacer (Invitrogen/
GIBCO) instead of foetal calf serum and passaged with an
enzymatic method (collagenase IV). They performed
interphase fluorescence in situ hybridization (FISH) and
showed that after 22 passages trisomy 17 was observed in
76% of the cells and after an additional 17 passages, in 95%
of the cells, again indicating that such cells possess
enhanced survival or proliferation properties. Buzzard and
colleagues [6] cultured six NIH-registered HESC lines
(hES1-6) between 34 and 140 passages using mechanical
method of passaging cells rather than enzymatic or
chemical methods of cell dissociation. They reported just
one karyotype abnormality was detected in an early passage
hES5, demonstrating that HESCs are not necessarily
predisposed to karyotypic abnormalities even grown for
extended time. Another group studied 3 cell lines (BG01,
BG02 and BG03) and showed that karyotypic changes also
give rise to differences in expression of genes, especially
those involved in pluripotency [24]. They reported that bulk
passaging (nonenzymatic- Cell Dissociation Buffer- or
enzymatic- colagenase, trypsin) methods can compromise
the genetic stability of HESCs, in contrast with manual
methods. The bulk passage methods can be used for shorter
periods (<passage 15) without problems.
Because classical G-band karyotype can only give a
rough idea of chromosomal stability, techniques with more
resolution should be used to detect smaller chromosomal
and gene alterations/mutations. So other studies attempt to
overcome that problem by using techniques, like SNP, to
track down these alterations on HESCs, especially those
that are cultured for long periods of time. Maitra and
colleagues [21] compared 9 hESCs lines (BG01, BG02,
BG03, H1, H7, H9, HES-2, HES-3, SA001 and SA002)
derived and cultured in different laboratories at both early
and late passage and found the former ones can develop
one or more genomic alterations commonly observed in
human cancers, mitochondrial DNA sequence mutations
and gene promoter methylation. Enver et al. [9] investi-
gated the adaptation process by comparing early passage
(normal) and late passage (adapted) sublines of H7. The
karyotype of early passage cells was normal, whereas the
adapted showed an extra copy of chromosome 1 and
chromosome 17q amplification. Slightly higher proportion
of SSEA3+ cells were found in the adapted cultures as
compared to the normal ones (83 and 64%, respectively).
They also showed failure in X-inactivation, suggesting that
epigenetic changes are also associated with adaptation.
Thus the mechanism of adaptation may be similar to the
early events involved in oncogenesis and tumor progres-
sion. Baker et al. [3] have made an attempt to link culture
adaptation and malignancy. In agreement with other
laboratories they also observed a nonrandom gain of certain
regions in the three mainly affected chromosomes in HESC
(12, 17 and X). They hypothesized that these chromosomes
may contain candidate genes that could be important for the
observed culture adaptation and/or play a role in stem cell
maintenance in vitro and cell tumorogenesis in vivo. One of
these candidate genes present in terminal half of q arm of
chromosome 17 is BIRC5, also known as Survivin.
Survivin can act as an antiapoptotic gene and also plays a
role in chromosome segregation. Survivin is expressed in a
large number of tumor types such as neuroblastomas and
associated with highest-risk tumors and poor survival
outcome. Gain of chromosome 12 was also frequently
observed in both HESCs and testicular germ cell tumors
(TGCTs). Nanog, a pluripotency gene, is located on 12p13
and overexpression of this gene promotes self-renewal
and prevents differentiation and thus can give hESC an
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anti-differentiation and proliferation advantage in culture.
Another amplified region on chromosome 12, 12p11.2–12
that is also frequently amplifies in TGCTs harbours the
oncogene K-RAS and SOX5, a gene involved in cell fate
determination. Reduced apoptosis has been observed in
malignant cells with this amplification and it is possible that
amplification of this region may confer a similar survival
advantage to hESC. Multiple studies have found that hESC
acquire additional copies of chromosome X and often
TGCTs have more than one X chromosome. Enver et al.
further identified ELK1, A-RAF, the androgen receptor and
its interacting protein NONO, as potential candidate genes
on X that could be involved in hESC adaptation.
The non random gain of chromosomes 12, 17 and X
observed in different hESC lines in different laboratories
around the world lends support to the hypothesis that there
may be genes on these chromosomes that confer a growth or
anti-differentiation advantage to hESC in culture. Generat-
ing small clumps or single cells from hESC colonies in
general leads to apoptosis and differentiation. The fact these
abnormalities only occur in bulk cultured cells suggests that
the seeding of small clumps of hESC puts selective pressure
on hESC that favours hESC with such genetic abnormali-
ties. In this context increased expression of genes that
inhibit apoptosis (and differentiation) of hESC, such as
CD30, prior to overt genetic abnormalities may increase the
likelihood of acquiring further abnormalities.
hESC and CD30
We discovered that hESC cultured under bulk culture
conditions rapidly start to express the CD30 antigen, a
molecule that marks embryo carcinoma and Hodgkin
lymphoma cells [7]. Overexpression of CD30 in Hodgkin
lymphoma leads to ligand independent activation of
downstream signalling activating MEK-ERK, AKT and
NF-k-B pathways. Interestingly, these pathway were also
identified as important regulators of stem cell maintenance.
Moreover, CD30 may be directly involved in the genetic
stability and transformation of hESC since it’s overexpres-
sion leads to transformation of rat fibroblasts [26]. In
agreement with a possible role of CD30 in hESC genetic
stability, we previously were able to show that CD30 is a
biomarker for genetically abnormal hESC and causes both
increased NF-k-B activity and inhibition of apoptosis and is
associated with b-FGF independent expression of pluripo-
tency markers. It remains to be established whether CD30
expression is a bystander/indicator of these phenotypes or is
responsible for all or some of these properties. Importantly,
preliminary data from our laboratory indicate that CD30
expressing hESC display a reduced expression of p53 and
an increase in survivin (BRC5) expression, suggesting that
signalling downstream of CD30 may affect the expression
of genes involved in genetic stability and chromosome
segregation. An example of how CD30 expressing hESC
phenotypically differ from CD30 negative hESC is
uncovered when hESC are cultured under feeder free
conditions. Feeder free HESC cultures involves seeding of
bulk-culture grown hESC on matrigel coated dishes in the
presence of feeder conditioned medium [34]. This has the
advantage that it removes the physical interaction with the
feeder layers and can thus be used to identify the growth
factors excreted by the feeders that evidently are able to
maintain hESC undifferentiated growth. It is however
important that the hESC used in such methods are early
passage hESC that have not undergone changes such as
b-FGF independence and CD30 expression since in our
experience genetically abnormal hESC or hESC that highly
express CD30 have lost the ability to spontaneously
differentiate in the absence of the feeder conditioned
medium over a 2 week period and can thus no longer be
used to identify maintenance factors. This highlights the
importance of testing hESC cultured on matrigel with
feeder conditioned medium for spontaneous differentiation
in the absence of conditioned medium before claiming the
identification of factors that maintain hESC in the absence
of feeders.
Epigenetics and Genomic Stability
As was shown by Jaenisch et al., using an elegant model of
transient DNMT1 inactivation in mouse ES-cells to
generate imprint free ES cells, loss of methylation in ES
cells is directly related to tumorigenesis [15]. Loss of
imprinting leads to a higher growth rate, a shortened cell
cycle time, cellular immortality, resistance to TGFβ, and
foci formation on a confluent monolayer. Consistent with
this, imprint free-MEFs formed tumors in SCID mice and
adult chimeric mice derived from IF-ES cells developed
tumors in multiple tissues that were originally derived from
the IF-ES cells. It appears therefore that imprinting plays a
much wider role in tissue homeostasis than just regulating
normal embryonic growth and is directly responsible for
providing critical tumor suppressor activity in the mature
organism. The next challenge will be to identify the genes
whose methylation status/silencing is critical for this
function. Igf2/H19 was previously indicated but was
variably methylated in the Jaenisch study. It appears
however that loss of imprinting confers immortality to
MEFs by inactivating the Arf-p53 pathway, but the
mechanisms responsible remain to be elucidated. In light
of these recent discoveries it is interesting to note that
human ES cells were found to undergo a range of
epigenetic modification upon prolonged culture in serum
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free culture conditions, including dramatic changes in
methylation.
miRNA in hESCs
microRNAs (miRNAs) are an abundant class of endoge-
nous non-protein-coding small RNAs, which negatively
regulate gene expression at the posttranscriptional level in
many developmental and metabolic processes. miRNAs
regulate a variety of biological processes, including
developmental timing, signal transduction, tissue differen-
tiation and maintenance, disease, and carcinogenesis. It is
increasingly recognized that miRNAs also play an
essential role in stem cell self-renewal and differentiation.
Some miRNAs are specifically expressed in stem cells
and could be involved in controlling stem cell self-
renewal and differentiation by negatively regulating the
expression of certain key genes in stem cells. Dicer, an
enzyme complex involved in miRNA processing, is
essential for mammalian development, with Dicer-defi-
cient mice dying at embryonic day 7.5 with a lack of
detectable multipotent stem cells [18, 24]. Dicer loss
compromises maturation of miRNAs and leads to a defect
in gene silencing triggered by long dsRNAs. However, the
absence of Dicer does not affect the ability of small
interfering RNAs to repress gene expression. Importantly,
Dicer loss compromises the proliferation of ES cells,
which may explain the phenotype of DICER null mice.
DGCR8 is another enzyme involved in nuclear processing
of pre-miRNA. Analysis of DGCR8 mouse knockout ES
cells shows that DGCR8 is essential for biogenesis of
miRNAs [33]. On the induction of differentiation,
DGCR8-deficient ES cells do not fully downregulate
pluripotency markers and retain the ability to produce
ES cell colonies. Thus miRNAs appear to play a role in
the silencing of ES cell self-renewal that normally occurs
with the induction of differentiation. There is evidence to
suggest that shRNA are able to be transported/diffuse
through GAP junctions between hESC. This opens up the
interesting possibility that hESC may also be signalling to
each other at a gene regulation level leading to a
communal effect between multiple stem cells connected
by GAP junctions. It remains to be established whether
this phenomenon could explain the inability of hESC to
grow from single cells and how this relates to the role of
miRNAs in differentiation and self renewal.
The Role of p53 in hESC
DNA damage response and cell-cycle regulation differ
markedly between mouse embryonic stem cells (mESCs)
and somatic cells [16]. ES cells require sensitive mecha-
nisms to maintain genomic integrity and do so, in part, by
suppressing spontaneous mutation. Spontaneous mutation
frequency in somatic cells is approximately 10(−4) com-
pared with 10(−6) for mESCs cells. mESCs cells also lack a
G1 checkpoint and are hypersensitive to IR and other
DNA-damaging agents [16]. These characteristics facilitate
apoptosis and the removal of cells with a mutational burden
from the population, thereby keeping the population free of
damaged cells. Nucleotide excision repair in mESCs
exposed to genotoxic effects of UV-induced DNA damage
is not very efficient and leads to induction of apoptosis
[32], further indicating that ES cells favor the induction of
apoptosis to avoid accumulation of transformed cells.
Array studies indicate that p53 and other genes involved
in apoptosis are expressed in on hESC and mESC [3, 10,
27]. Array analysis of H1 cells showed [10] that ES cells
express p53, MDM2 a negative regulator of p53, the pro-
apoptotic downstream target of p53 Bax, as well as the
BAX related genes BAK, HRK and the Bcl-2 family
member MCL-1. Therefore the basic machinery for
cytochrome c release and apoptosome activation is present
in hESC.
P53 is considered a critical regulator of genomic
integrity because of its ability to trigger apoptosis and/or
cell cycle arrest in response to genotoxic stress. Indeed,
mutations of the p53 gene occur in approximately 50% of
human cancers [14, 17, 20]. P53 can be involved in
maintaining genetic stability in several ways. P53 exerts
control over both the G2/M and the G1 cell cycle
checkpoints. P53 inactivation can synergize with oncogene
activation leading to aneuploidy and chromosome imbal-
ance. We speculate that if p53 pathway is altered in stem
cells and an oncogene gets activated, these cells may have a
survival or growth advantage and take over the culture. p53
can also affect genetic stability through it’s ability to
regulate centrosome duplication via either transactivation
dependent mechanisms involving p21, or transactivation
independent mechanisms, by interacting directly with other
centrosomal proteins at the centrosome. Indeed, Survivin,
an inhibitor of apoptosis and a chromosomal passenger
protein whose deregulation leads to aneuplody, is negative-
ly regulated by p53. As mentioned earlier, Survivin is also
one of the candidate genes on the frequently duplicated
chromosome 17 and a gene upregulated in CD30 express-
ing hESC (Wolvetang pers.comm.).
The precise role of p53 in both mouse and human ES
cell apoptosis remains unclear. While some argue that p53
is non-functional in undifferentiated mESCs [1] others
show that p53 does have a role to play in both UV-induced
apoptosis [7, 35] as well as differentiation [29]. Qin et al.
[20] have recently shown that HESCs undergo p53
mediated-apoptosis induced by UV [27]. They further
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reported that relatively high rate of spontaneous apoptosis
of hESC in culture (10–15% daily) is controlled by p53. At
present it remains to be established whether this spontane-
ous apoptosis is due to suboptimal culture conditions or is
an intrinsic feature of hESC that is involved in eliminating
cells with acquired DNA damage.
Concluding Remarks
The development of genomic instability is central feature of
carcinogenesis and is difficult to study in a cell lines
because the molecular pathways involved in transformation
are altered during the establishment of a cell line. The
striking difference in genomic stability between hESC
cultured under standard conditions and hESC expanded in
“bulk” cultures offers a unique opportunity to study this
process in a non-transformed model system. We believe
that a better understanding of the interrelationship between
selection/adaptation and genetic/epigenetic regulation in
hESC will further our insight into the molecular processes
that control genomic stability and transformation. The
standardisation of assays to assess these parameters and
the standardisation of culture methods for hESC through
international collaborative initiatives will be critical for the
advancement of this body of knowledge.
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